DrugPatentWatch Database Preview

IDHIFA Drug Profile

« Back to Dashboard

Which patents cover Idhifa, and when can generic versions of Idhifa launch?

Idhifa is a drug marketed by Celgene Corp and is included in one NDA. There are four patents protecting this drug.

This drug has sixty-six patent family members in thirty-one countries.

The generic ingredient in IDHIFA is enasidenib mesylate. One supplier is listed for this compound. Additional details are available on the enasidenib mesylate profile page.

Summary for IDHIFA

International Patents:	66
US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	35
Clinical Trials:	3
Patent Applications:	22
Drug Prices:	Drug price information for IDHIFA
Prior Art and Litigation Support	Order Prior Art and Litigation support for IDHIFA
DailyMed Link:	IDHIFA at DailyMed

Generic Entry Opportunity Date for IDHIFA

NDA:

209606

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for IDHIFA

1446502-11-9

2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol

2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol

2-Methyl-1-[(4-[6-(Trifluoromethyl)pyridin-2-Yl]-6-{[2-(Trifluoromethyl)pyridin-4-Yl]amino}-1,3,5-Triazin-2-Yl)amino]propan-2-Ol

2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol

2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-

3T1SS4E7AG

69Q

AG 221

AG-221

AG-221 (Enasidenib)

AG-221; Enasidenib

AG-221(Enasidenib)

AG221

AKOS026750439

BCP16041

CC 90007

CC-90007

CC-90007 Free Base

CC90007

CHEMBL3989908

CS-5017

D10901

DB13874

Enasidenib

Enasidenib (USAN/INN)

Enasidenib [INN]

Enasidenib [USAN:INN]

Enasidenib mesylate

EX-A654

FT-0700204

GTPL8960

HY-18690

J-690181

KB-3356927

KS-000006AW

NCGC00479249-03

NCGC00479249-05

s8205

SB19193

SCHEMBL15102202

UNII-3T1SS4E7AG

ZINC222731806

US Patents and Regulatory Information for IDHIFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No			Y	Y
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes			Y	Y
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No				Y
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-002	Aug 1, 2017		RX	Yes	Yes			Y	Y
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No			Y	Y
Celgene Corp	IDHIFA	enasidenib mesylate	TABLET;ORAL	209606-001	Aug 1, 2017		RX	Yes	No				Y

International Patents for IDHIFA

Country	Patent Number	Estimated Expiration
Mexico	2014008350
Eurasian Patent Organization	201690322
China	105916507
Brazil	112016002287
Mexico	2016001361
Australia	2017265096
Japan	6411895